Document is current
Any future updates will be listed below
-
Authors
Salfi, Federico https://orcid.org/0000-0003-1961-286X
Amicucci, Giulia https://orcid.org/0000-0001-9975-6497
Ferrara, Michele https://orcid.org/0000-0003-2304-7576
Tempesta, Daniela https://orcid.org/0000-0002-6942-5336
De Berardinis, Andrea
Chiricozzi, Andrea https://orcid.org/0000-0002-6739-0387
Peris, Ketty https://orcid.org/0000-0003-1957-6600
Fargnoli, Maria Concetta https://orcid.org/0000-0002-7249-2556
Esposito, Maria https://orcid.org/0000-0002-4773-6993
-
Funding
Funding for this research was provided by:
Università degli Studi dell’Aquila
- License Information
-
More Information
Article History
Received: 21 July 2022
Revised: 26 October 2022
Accepted: 16 January 2023
First Online: 7 February 2023
Declarations
:
: A. Chiricozzi served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Leo Pharma, Lilly, Janssen, Novartis, Pfizer, and Sanofi Genzyme. K. Peris has served on advisory boards and received honoraria for lectures from Almirall, Abbvie, Lilly, Galderma, Leo Pharma, Pfizer, Pierre Fabre, Janssen, Novartis, Sanofi, Sun Pharma. MC Fargnoli has served on advisory boards, received honoraria for lectures and research grants from AMGEN, Almirall, Abbvie, BMS, Galderma, Kyowa Kyrin, Leo Pharma, Pierre Fabre, UCB, Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi-Regeneron, Sunpharma. M. Esposito has served as a speaker/board member for Abbvie, Almirall, Biogen, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis. F. Salfi, G. Amicucci, M. Ferrara, D. Tempesta, A. De Berardinis declared no conflicts of interests.
